Common TitleFLAIR
Official Title A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
Phase Phase III
ClinicalTrials.gov NCT02938520
Treatments
Injectable cabotegravir and Rilpivirine
Injectable cabotegravir and Rilpivirine
Tradename:CabenuvaClass:Long-Acting Injectable RegimensCategories Treatment-NaiveDual Therapy
Funding
IndustryViiV Healthcare and Janssen
References
- Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020;382:1124-35.